tiprankstipranks
Trending News
More News >
Connect Biopharma Holdings Ltd. (CNTB)
:CNTB
US Market
Advertisement

Connect Biopharma Holdings (CNTB) Stock Forecast & Price Target

Compare
96 Followers
See the Price Targets and Ratings of:

CNTB Analyst Ratings

Strong Buy
3Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
Based on 3 analysts giving stock ratings to
Connect
Biopharma Holdings
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CNTB Stock 12 Month Forecast

Average Price Target

$6.83
▲(217.67% Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Connect Biopharma Holdings in the last 3 months. The average price target is $6.83 with a high forecast of $7.50 and a low forecast of $6.00. The average price target represents a 217.67% change from the last price of $2.15.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","-1":"-$1","1.25":"$1.25","3.5":"$3.5","5.75":"$5.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.25,3.5,5.75,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Nov<br/>2024","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2,2.423076923076923,2.8461538461538463,3.269230769230769,3.6923076923076925,4.115384615384615,4.538461538461538,4.961538461538462,5.384615384615385,5.8076923076923075,6.230769230769231,6.653846153846154,7.076923076923077,{"y":7.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2,2.3715384615384614,2.743076923076923,3.1146153846153846,3.4861538461538464,3.8576923076923078,4.229230769230769,4.600769230769231,4.972307692307693,5.343846153846154,5.7153846153846155,6.086923076923077,6.458461538461538,{"y":6.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2,2.3076923076923075,2.6153846153846154,2.9230769230769234,3.230769230769231,3.5384615384615383,3.8461538461538463,4.153846153846154,4.461538461538462,4.769230769230769,5.076923076923077,5.384615384615385,5.6923076923076925,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.36,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.36,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.36,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.79,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.6,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.57,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.82,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$7.50Average Price Target$6.83Lowest Price Target$6.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on CNTB
Leerink Partners
Leerink Partners
$6
Buy
179.07%
Upside
Reiterated
08/14/25
Connect Biopharma Holdings (CNTB) Receives a Rating Update from a Top Analyst
H.C. Wainwright Analyst forecast on CNTB
H.C. Wainwright
H.C. Wainwright
$7
Buy
225.58%
Upside
Reiterated
08/13/25
Promising Developments and Strategic Moves Justify Buy Rating for Connect Biopharma HoldingsValuation and Risks. We base our valuation on our probability-weighted clinical net present value (NPV) discounted cash flow valuation model. We use a weighted average cost of capital of 16.2% in our discounted cash flow, and an exit multiple of 10.0x our 2036 estimates.Our peak sales estimates assume a 55% probability of success for rademikibart in acute exacerbations in the 15% probability of success for rademikibart in the EU.
Northland Securities Analyst forecast on CNTB
Northland Securities
Northland Securities
$7.5
Buy
248.84%
Upside
Initiated
07/22/25
Connect Biopharma initiated with an Outperform at NorthlandConnect Biopharma initiated with an Outperform at Northland
TR | OpenAI - 4o Analyst forecast on CNTB
TR | OpenAI - 4o
TR | OpenAI - 4o
Hold
Reiterated
04/26/25
AI Generated ArticleAI Generated Article
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on CNTB
Leerink Partners
Leerink Partners
$6
Buy
179.07%
Upside
Reiterated
08/14/25
Connect Biopharma Holdings (CNTB) Receives a Rating Update from a Top Analyst
H.C. Wainwright Analyst forecast on CNTB
H.C. Wainwright
H.C. Wainwright
$7
Buy
225.58%
Upside
Reiterated
08/13/25
Promising Developments and Strategic Moves Justify Buy Rating for Connect Biopharma HoldingsValuation and Risks. We base our valuation on our probability-weighted clinical net present value (NPV) discounted cash flow valuation model. We use a weighted average cost of capital of 16.2% in our discounted cash flow, and an exit multiple of 10.0x our 2036 estimates.Our peak sales estimates assume a 55% probability of success for rademikibart in acute exacerbations in the 15% probability of success for rademikibart in the EU.
Northland Securities Analyst forecast on CNTB
Northland Securities
Northland Securities
$7.5
Buy
248.84%
Upside
Initiated
07/22/25
Connect Biopharma initiated with an Outperform at NorthlandConnect Biopharma initiated with an Outperform at Northland
TR | OpenAI - 4o Analyst forecast on CNTB
TR | OpenAI - 4o
TR | OpenAI - 4o
Hold
Reiterated
04/26/25
AI Generated ArticleAI Generated Article
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Connect Biopharma Holdings

1 Month
xxx
Success Rate
7/13 ratings generated profit
54%
Average Return
-1.33%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 53.85% of your transactions generating a profit, with an average return of -1.33% per trade.
3 Months
xxx
Success Rate
7/13 ratings generated profit
54%
Average Return
-0.72%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 53.85% of your transactions generating a profit, with an average return of -0.72% per trade.
1 Year
Thomas SmithLeerink Partners
Success Rate
7/13 ratings generated profit
54%
Average Return
+26.77%
reiterated a buy rating 3 days ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +26.77% per trade.
2 Years
xxx
Success Rate
8/13 ratings generated profit
62%
Average Return
+54.25%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 61.54% of your transactions generating a profit, with an average return of +54.25% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CNTB Analyst Recommendation Trends

Rating
Mar 25
Apr 25
Jun 25
Jul 25
Aug 25
Strong Buy
1
1
2
3
5
Buy
0
0
0
0
0
Hold
1
4
3
3
0
Sell
2
1
0
0
0
Strong Sell
0
0
0
0
0
total
4
6
5
6
5
In the current month, CNTB has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CNTB average Analyst price target in the past 3 months is 6.83.
Each month's total comprises the sum of three months' worth of ratings.

CNTB Financial Forecast

CNTB Earnings Forecast

Next quarter’s earnings estimate for CNTB is -$0.22 with a range of -$0.22 to -$0.22. The previous quarter’s EPS was ―. CNTB beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.19% of the time in the same period. In the last calendar year CNTB has Outperformed its overall industry.
Next quarter’s earnings estimate for CNTB is -$0.22 with a range of -$0.22 to -$0.22. The previous quarter’s EPS was ―. CNTB beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.19% of the time in the same period. In the last calendar year CNTB has Outperformed its overall industry.

CNTB Sales Forecast

Next quarter’s sales forecast for CNTB is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were ―. CNTB beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.39% of the time in the same period. In the last calendar year CNTB has Outperformed its overall industry.
Next quarter’s sales forecast for CNTB is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were ―. CNTB beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.39% of the time in the same period. In the last calendar year CNTB has Outperformed its overall industry.

CNTB Stock Forecast FAQ

What is CNTB’s average 12-month price target, according to analysts?
Based on analyst ratings, Connect Biopharma Holdings Ltd.’s 12-month average price target is 6.83.
    What is CNTB’s upside potential, based on the analysts’ average price target?
    Connect Biopharma Holdings Ltd. has 217.67% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CNTB a Buy, Sell or Hold?
          Connect Biopharma Holdings Ltd. has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Connect Biopharma Holdings Ltd.’s price target?
            The average price target for Connect Biopharma Holdings Ltd. is 6.83. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $7.50 ,the lowest forecast is $6.00. The average price target represents 217.67% Increase from the current price of $2.15.
              What do analysts say about Connect Biopharma Holdings Ltd.?
              Connect Biopharma Holdings Ltd.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
                How can I buy shares of CNTB?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis